# Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML)

> **NCT01488344** · PHASE1,PHASE2 · UNKNOWN · sponsor: **University Hospital Muenster** · enrollment: 140 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** triple kinase inhibitor BIBF1120

## Key facts

- **NCT ID:** NCT01488344
- **Lead sponsor:** University Hospital Muenster
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-03
- **Primary completion:** 2014-11
- **Final completion:** —
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2013-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01488344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01488344, "Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT01488344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*